Completed PHASE3 INTERVENTIONAL 1-arm NCT00424372

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia

A LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY STUDY OF PREGABALIN IN THE TREATMENT OF POSTHERPETIC NEURALGIA.

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Interventions pregabalin

Updated 6 times since 2017 Last updated: Jul 30, 2021 Started: Jan 12, 2007 Primary completion: Aug 19, 2008 Completion: Aug 19, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Neuralgia, Postherpetic, this trial is completed. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akashi, Japan , Amagasaki, Japan , Arakawa-ku, Japan , Asahikawa, Japan , Beppu, Japan , Bunkyo-ku, Japan , Fukuoka, Japan , Fukushima, Japan , Himeji, Japan , Kasuya-gun, Japan and 16 more locations